Iron and infection in hemodialysis patients.

Iron and infection in hemodialysis patients.
复制标题

血液透析患者的铁和感染。

DOI:
10.1111/sdi.12168
复制
发表时间:
2014-01
影响因子:
1.6
通讯作者:
Johansen KL
Johansen KL
中科院分区:
医学3区
文献类型:
--
作者:
Ishida JH;Johansen KL

文献摘要

参考文献

被引文献

相似文献

静脉铁剂是治疗终末期肾病(ESRD)贫血的重要组成部分,但从生物学角度来看,铁剂可能通过损害中性粒细胞和T细胞功能以及促进微生物生长而增加感染风险。由于感染是透析患者死亡和发病的重要原因,因此任何此类风险增加都将特别重要。总体证据支持血液透析患者铁与感染之间的相关性,但最佳的铁管理策略,以尽量减少感染风险尚未确定。有必要对这一主题进行进一步研究,特别是考虑到在实施捆绑式ESRD报销系统后静脉铁剂的使用增加。
Intravenous iron is an important component of the treatment of anemia of end-stage renal disease (ESRD), but it is biologically plausible that iron could increase the risk of infection through impairment of neutrophil and T cell function and promotion of microbial growth. Any such increase in risk would be particularly important because infection is a significant cause of mortality and morbidity in dialysis patients. The overall evidence favors an association between iron and infection in hemodialysis patients, but the optimal iron management strategy to minimize infection risk has yet to be identified. There is a need for further research on this topic, particularly in light of increased utilization of intravenous iron following implementation of the bundled ESRD reimbursement system.
DOI: 10.1093/ndt/5.2.130
发表时间: 1990-02-01
影响因子: 6.1
作者:
BOELAERT, JR;DANEELS, RF;VANLANDUYT, HW
通讯作者: VANLANDUYT, HW
DOI: 10.1046/j.1523-1755.2003.00125.x
发表时间: 2003-08-01
影响因子: 19.6
作者:
Deicher, R;Ziai, F;Hörl, WH
通讯作者: Hörl, WH
DOI: 10.1681/asn.2012121164
发表时间: 2013-07-01
影响因子: 13.6
作者:
Brookhart, M. Alan;Freburger, Janet K.;Kshirsagar, Abhijit V.
通讯作者: Kshirsagar, Abhijit V.
DOI: 10.1046/j.1525-1594.2001.06894.x
发表时间: 2001-11-01
期刊: ARTIFICIAL ORGANS
影响因子: 2.4
作者:
Canziani, MEF;Yumiya, ST;Draibe, SA
通讯作者: Draibe, SA